Abstract
Recently, a nonsense alteration Trp149Stop in the ARLTS1 gene was found more frequently in familial cancer cases versus sporadic cancer patients and healthy controls. Here, the role of Trp149Stop or any other ARLTS1 germline variant was evaluated on breast, prostate, and colorectal cancer risk. The whole gene was screened for germline alterations in 855 familial cancer patients. The five observed variants were further screened in 1169 non-familial cancer patients as well as in 809 healthy population controls. The Trp149Stop was found at low frequencies (0.5–1.2%) in all patient subgroups versus 1.6% in controls, and the mutant allele did not co-segregate with disease status in families with multiple affected individuals. The CC genotype in the Cys148Arg variant was slightly more common among both familial and sporadic breast (odds ratio (OR), 1.48; 95% confidence interval (CI), 1.16–1.87; P=0.001) and prostate cancer patients (OR, 1.50; 95% CI, 1.13–1.99; P=0.005) when compared to controls. A novel ARLTS1 variant Gly65Val was found at higher frequency among familial prostate cancer patients (8 of 164, 4.9%) than in controls (13 of 809, 1.6%; OR, 3.14; 95% CI, 1.28–7.70, P=0.016). However, after adjusting for multiple testing, none of these results were still significant. No association was found with any of the variants and colorectal cancer risk. Our results suggest that Trp149Stop is not a predisposition allele in breast, prostate, or colorectal cancer in the Finnish population, and, while the Gly65Val variant may increase familial prostate cancer risk and the Cys148Arg change may affect both breast and prostate cancer risk, the evidence is not strong in these data.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Lichtenstein P, Holm NV, Verkasalo PK et al: Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78–85.
Kilpivaara O, Alhopuro P, Vahteristo P, Aaltonen LA, Nevanlinna H : CHEK2 I157T associates with familial and sporadic colorectal cancer. J Med Genet 2006; 43: e34.
Kilpivaara O, Vahteristo P, Falck J et al: CHEK2 variant I157T may be associated with increased breast cancer risk. Int J Cancer 2005; 111: 543–547.
Seppälä EH, Ikonen T, Mononen N et al: CHEK2 variants associate with hereditary prostate cancer. Br J Cancer 2003; 89: 1966–1970.
Calin GA, Trapasso F, Shimizu M et al: Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med 2005; 352: 1667–1676.
Frank B, Klaes R, Burwinkel B : Familial cancer and ARLTS1. N Engl J Med 2005; 353: 313–314; author reply 313–314.
Frank B, Hemminki K, Meindl A et al: Association of the ARLTS1 Cys148Arg variant with familial breast cancer risk. Int J Cancer 2006; 118: 2505–2508.
Frank B, Meyer P, Boettger MB et al: ARLTS1 variants and melanoma risk. Int J Cancer 2006; 119: 1736–1737.
Frank B, Hemminki K, Brenner H, Hoffmeister M, Chang-Claude J, Burwinkel B : ARLTS1 variants and risk of colorectal cancer. Cancer Lett 2006; 244: 172–175.
Castellví-Bel S, Castells A, de Cid R et al: Association of the ARLTS1 Cys148Arg variant with sporadic and familial colorectal cancer. Carcinogenesis 2007; 28: 1687–1691.
Sellick GS, Catovsky D, Houlston RS : Relationship between ARLTS1 polymorphisms and risk of chronic lymphocytic leukemia. Leuk Res 2006; 30: 1573–1576.
Petrocca F, Iliopoulos D, Qin HR et al: Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer. Cancer Res 2006; 66: 10287–10291.
Syrjäkoski K, Vahteristo P, Eerola H et al: Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 2000; 92: 1529–1531.
Seppälä EH, Ikonen T, Autio V et al: Germ-line alterations in MSR1 gene and prostate cancer risk. Clin Cancer Res 2003; 9: 5252–5256.
Aaltonen LA, Salovaara R, Kristo P et al: Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998; 338: 1481–1487.
Salovaara R, Loukola A, Kristo P et al: Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 2000; 18: 2193–2200.
Eerola H, Blomqvist C, Pukkala E, Pyrhonen S, Nevanlinna H : Familial breast cancer in southern Finland: how prevalent are breast cancer families and can we trust the family history reported by patients? Eur J Cancer 2000; 36: 1143–1148.
Vahteristo P, Eerola H, Tamminen A, Blomqvist C, Nevanlinna H : A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Br J Cancer 2001; 84: 704–708.
Gabriel SB, Schaffner SF, Nguyen H et al: The structure of haplotype blocks in the human genome. Science 2002; 296: 2225–2259.
Qin ZS, Niu T, Liu JS : Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms. Am J Hum Genet 2002; 71: 1242–1247.
Abudugupur A, Mitsui K, Yokota S, Tsurugi K : An ARL1 mutation affected autophagic cell death in yeast, causing a defect in central vacuole formation. Cell Death Differ 2002; 9: 158–168.
Gauderman WJ : Sample size requirements for matched case-control studies of gene-environment interaction. Stat Med 2002; 21: 35–50.
Pasqualato S, Renault L, Cherfils J : Arf, Arl, Arp and Sar proteins: a family of GTP-binding proteins with a structural device for ‘front-back’ communication. EMBO Rep 2002; 3: 1035–1041.
Latil A, Chêne L, Mangin P, Fournier G, Berthon P, Cussenot O : Extensive analysis of the 13q14 region in human prostate tumors: DNA analysis and quantitative expression of genes lying in the interval of deletion. Prostate 2003; 57: 39–50.
Valeri A, Fromont G, Sakr W et al: High frequency of allelic losses in high-grade prostate cancer is associated with biochemical progression after radical prostatectomy. Urol Oncol 2005; 23: 87–92.
Rökman A, Koivisto PA, Matikainen MP et al: Genetic changes in familial prostate cancer by comparative genomic hybridization. Prostate 2001; 46: 233–239.
Xu J, Dimitrov L, Chang BL et al: A combined genomewide linkage scan of 1233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet 2005; 77: 219–229.
Kainu T, Juo SH, Desper R et al: Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. Proc Natl Acad Sci USA 2000; 97: 9603–9608.
Acknowledgements
We thank Sini Marttinen, Iina Vuoristo, Minna Sjöblom, Ian Dusenberry, and John Zhou for their assistance. This study has been financially supported by the Academy of Finland (grants 212901, 211123, 118413, 110663), Finnish Cancer Society, Sigrid Juselius Foundation, Foundation of the Finnish Cancer Institute, the Medical Research Fund of Tampere University Hospital, The Helsinki University Hospital Research Fund, the Reino Lahtikari Foundation, and the Intramural Research Program of the National Human Genome Research Institute, National Institutes of Health, USA.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on European Journal of Human Genetics website (http://www.nature.com/ejhg)
Supplementary information
Rights and permissions
About this article
Cite this article
Siltanen, S., Syrjäkoski, K., Fagerholm, R. et al. ARLTS1 germline variants and the risk for breast, prostate, and colorectal cancer. Eur J Hum Genet 16, 983–991 (2008). https://doi.org/10.1038/ejhg.2008.43
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/ejhg.2008.43
Keywords
This article is cited by
-
ARL9 is upregulated and serves as a biomarker for a poor prognosis in colon adenocarcinoma
BMC Gastroenterology (2023)
-
ARLTS1 polymorphism is associated with an increased risk of familial cancer: evidence from a meta-analysis
Hereditary Cancer in Clinical Practice (2017)
